Wall Street Zen upgraded shares of Invivyd (NASDAQ:IVVD – Free Report) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.
A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Invivyd in a research note on Thursday, August 27th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research note on Monday, November 16th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research note on Tuesday, September 29th. Finally, Weiss Ratings upgraded shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.
Check Out Our Latest Stock Analysis on Invivyd
Invivyd Stock Performance
NASDAQ IVVD opened at $0.41 on Friday. Invivyd has a fifty-two week low of $0.41 and a fifty-two week high of $3.01. The stock has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $1.06. The stock has a market cap of $122.01 million, a P/E ratio of -1.12 and a beta of 1.20.
Invivyd (NASDAQ:IVVD – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The firm had revenue of $15.45 million for the quarter, compared to analysts’ expectations of $15.04 million. Invivyd had a negative return on equity of 67.17% and a negative net margin of 214.77%. Sell-side analysts predict that Invivyd will post -0.51 earnings per share for the current year.
Institutional Investors Weigh In On Invivyd
A number of institutional investors have recently made changes to their positions in IVVD. Bank of New York Mellon Corp raised its holdings in Invivyd by 54.3% in the 1st quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after acquiring an additional 9,568 shares during the last quarter. SummitTX Capital L.P. bought a new stake in shares of Invivyd in the first quarter worth $37,000. Rangeley Capital LLC purchased a new stake in Invivyd during the first quarter valued at $58,000. The Manufacturers Life Insurance Company purchased a new stake in Invivyd during the second quarter valued at $52,000. Finally, Empowered Funds LLC bought a new stake in shares of Invivyd during the 3rd quarter valued at about $80,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Further Reading
- Five stocks we like better than Invivyd
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
